January 07, 2026

Protein-First Policy Hits US Tables 

New 2025 to 2030 Dietary Guidelines for Americans shift focus to whole foods, full-fat dairy, and protein prioritization while targeting ultraprocessed products as chronic disease drivers

Conexiant

January 02, 2026

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

Conexiant

December 23, 2025

FDA OKs First Oral GLP-1 for Obesity

An oral GLP-1 option entered obesity care with outcomes similar to injectable therapy.

Conexiant

December 17, 2025

First Inhaled ED Treatment Gets Green Light for Trials

Beta1's novel delivery system promises 10-minute onset, launching phase I trials in Taiwan next year.

Conexiant

December 16, 2025

FDA OKs Addyi for Postmenopausal Women

Flibanserin approved to treat hypoactive sexual desire disorder in postmenopausal patients under 65

Conexiant

December 03, 2025

Ranitidine’s return 'unlikely to provide greater clinical benefit'

New formulation incorporates stronger manufacturing controls and stability measures to prevent NDMA from forming.

Conexiant

November 21, 2025

Which Antidepressants Shift Physiology?

Researchers found differences in how antidepressants affect weight, blood pressure, heart rate, and other physiological parameters.

Conexiant

November 18, 2025

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Conexiant

November 10, 2025

FDA Proposes Removal of Box Warnings

The FDA proposed updates to menopausal hormone therapy labeling to reflect current evidence on benefits and risks.

Conexiant